Editorial Article: PARP inhibitors: A new frontier in the battle against cervical cancer
Dr. Santu Saha shares his team’s groundbreaking work to develop improved cancer treatments to avoid the potential side effects of chemotherapy
05 Feb 2021
Dr. Santu Saha, Newton International Fellow of the Academy of Medical Sciences, Newcastle University
In this exclusive interview, we hear from Dr. Santu Saha about his ongoing research into effective new ways to treat cervical cancer. Dr. Saha, a Newton International fellow of the Academy of Medical Sciences working at Newcastle University, U.K., outlines how a DNA damage response pathway inhibitor, i.e. poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), can be used to serve as reliable cancer therapies to ameliorate cisplatin toxicity whilst also targeting hypoxic tumor cells for the treatment of cervical and other cancers, where cisplatin-based chemo-radiotherapy is the standard treatment.